INT119904

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2003
Last Reported 2008
Negated 3
Speculated 1
Reported most in Body
Documents 25
Total Number 26
Disease Relevance 9.36
Pain Relevance 8.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CYP19A1) small molecule metabolic process (CYP19A1) endoplasmic reticulum (CYP19A1)
cytoplasm (CYP19A1)
Anatomy Link Frequency
placentas 2
osteoblasts 1
ovary 1
CYP19A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 39 100.00 Very High Very High Very High
methadone 30 100.00 Very High Very High Very High
opiate 23 100.00 Very High Very High Very High
Buprenorphine 18 100.00 Very High Very High Very High
rheumatoid arthritis 68 99.90 Very High Very High Very High
Osteoarthritis 50 99.22 Very High Very High Very High
Inflammation 52 99.10 Very High Very High Very High
endometriosis 141 95.56 Very High Very High Very High
cINOD 40 94.16 High High
Analgesic 5 81.96 Quite High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 68 99.90 Very High Very High Very High
Breast Cancer 133 99.84 Very High Very High Very High
Endometriosis 132 99.64 Very High Very High Very High
Reprotox - General 3 267 99.36 Very High Very High Very High
Frailty 50 99.22 Very High Very High Very High
INFLAMMATION 58 99.10 Very High Very High Very High
Male Infertility 24 98.40 Very High Very High Very High
Obesity 75 96.92 Very High Very High Very High
Adhesions 26 94.80 High High
Malignant Neoplastic Disease 11 92.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Data obtained indicated that the opiates increased, inhibited, or had no effect on aromatase activity.
Neg (no) Regulation (effect) of aromatase associated with opiate
1) Confidence 0.62 Published 2007 Journal Biochem. Pharmacol. Section Abstract Doc Link 17118343 Disease Relevance 0 Pain Relevance 1.35
The effect of opiates on the activity of human placental aromatase/CYP19.
Regulation (effect) of aromatase associated with opiate
2) Confidence 0.62 Published 2007 Journal Biochem. Pharmacol. Section Title Doc Link 17118343 Disease Relevance 0 Pain Relevance 1.20
The other aromatase inhibitors (steroidal androstenedione analogues) were irreversible in their effect on the aromatase enzyme besides being parentrally administered.
Regulation (effect) of aromatase enzyme
3) Confidence 0.48 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.13 Pain Relevance 0
Taken together, these data indicate that CYP19/aromatase is the major enzyme responsible for the metabolism of methadone to EDDP in term human placentas obtained from healthy pregnancies.
Regulation (responsible) of CYP19 in placentas associated with methadone
4) Confidence 0.45 Published 2004 Journal Biochem. Pharmacol. Section Abstract Doc Link 15242824 Disease Relevance 0 Pain Relevance 0.55
In conclusion, third-generation aromatase inhibitors are effective and well tolerated.
Regulation (effective) of aromatase
5) Confidence 0.42 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001219 Disease Relevance 0.36 Pain Relevance 0
A single dose regimen would satisfy two goals: first, achieving maximum estrogen suppression early in the menstrual cycle when it is desired, and second, to allow clearance of the aromatase inhibitor before the critical final stage of fertilization and embryogenesis, to maximize safety and avoid any possible undesirable effects of the aromatase inhibitors.
Spec (possible) Regulation (effects) of aromatase
6) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0 Pain Relevance 0.03
This is because the available aromatase inhibitors were not safe for clinical application during ovarian stimulation due to lack of specificity in inhibiting the aromatase enzyme without inhibiting other steroidogenesis enzymes (e.g. aminoglutethimide).
Neg (not) Regulation (safe) of aromatase
7) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.15 Pain Relevance 0
To address the direct effect of aromatase inhibitors 3a and 4a on the proliferation of MCF-7aro cells, thymidine incorporation assays were performed.
Regulation (effect) of aromatase
8) Confidence 0.34 Published 2008 Journal BMC Cell Biol Section Body Doc Link PMC2515307 Disease Relevance 0 Pain Relevance 0
Due to the similar pharmacokinetics and pharmacodynamics, including similar potencies and specificity in inhibiting the aromatase enzyme, we believe there is likely to be no difference between the third generation aromatase inhibitors in their efficacy for ovarian stimulation.
Neg (no) Regulation (difference) of aromatase
9) Confidence 0.31 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.22 Pain Relevance 0
These directions for research would include: confirming the available preliminary data on the success of aromatase inhibition in induction and augmentation of ovulation, as well as reducing the dose of FSH needed for ovarian stimulation, improving response in poor responders, and finding the optimum regimen for administering aromatase inhibitors for infertility treatment
Regulation (administering) of aromatase associated with reprotox - general 3
10) Confidence 0.31 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.60 Pain Relevance 0.04
This underlines that inflammation in OA, apparently similar to that in RA, up-regulates aromatase activity leading to elevated levels of estrogens in synovial tissue.
Regulation (regulates) of aromatase associated with inflammation, rheumatoid arthritis and osteoarthritis
11) Confidence 0.29 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1257423 Disease Relevance 1.56 Pain Relevance 0.63
It has recently been discovered that up-regulation of COX-2 and correlative production of prostaglandin E2 (PGE2) effectively and specifically induces the promoter II region of the cytochrome P-450 gene (CYP-19) which is transcribed and translated into aromatase, the chief enzyme in the biosynthesis of estrogen 47, 48.
Regulation (translated) of CYP-19
12) Confidence 0.29 Published 2007 Journal International Journal of Biological Sciences Section Body Doc Link PMC1893117 Disease Relevance 0.79 Pain Relevance 0
Our current hypothesis is that pharmacological regulation of aromatase and/or cyclooxygenases can act locally to decrease the biosynthesis of estrogen and may provide additional therapy options for patients with hormone-dependent breast cancer.
Regulation (regulation) of aromatase associated with breast cancer
13) Confidence 0.27 Published 2007 Journal J. Steroid Biochem. Mol. Biol. Section Abstract Doc Link 17616393 Disease Relevance 0.48 Pain Relevance 0.19
Thus, these results suggest that the siRNAs and novel sulfonanilides targeting aromatase expression may be valuable tools for selective regulation of aromatase in breast cancer.
Regulation (regulation) of aromatase associated with breast cancer
14) Confidence 0.27 Published 2007 Journal J. Steroid Biochem. Mol. Biol. Section Abstract Doc Link 17616393 Disease Relevance 0.37 Pain Relevance 0
In summary, pharmacological regulation of aromatase and cyclooxygenases can act locally in an autocrine fashion to decrease the biosynthesis of estrogen and may provide additional therapy options for patients with hormone-dependent breast cancer.
Regulation (regulation) of aromatase associated with breast cancer
15) Confidence 0.27 Published 2005 Journal J. Steroid Biochem. Mol. Biol. Section Abstract Doc Link 15964185 Disease Relevance 0.42 Pain Relevance 0.22
The effect of opiates on the activity of human placental aromatase/CYP19.
Regulation (effect) of CYP19 associated with opiate
16) Confidence 0.26 Published 2007 Journal Biochem. Pharmacol. Section Title Doc Link 17118343 Disease Relevance 0 Pain Relevance 1.21
The effect of methadone and buprenorphine on human placental aromatase.
Regulation (effect) of aromatase associated with methadone and buprenorphine
17) Confidence 0.24 Published 2006 Journal Biochem. Pharmacol. Section Title Doc Link 16455059 Disease Relevance 0 Pain Relevance 1.28
Aromatase is a good target for selective inhibition because estrogen production is a terminal step in the biosynthetic sequence.
Regulation (target) of Aromatase
18) Confidence 0.21 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.51 Pain Relevance 0
They target the aromatase enzyme (a P-450 cytochrome enzyme), which converts testosterone and adrenal androgens to estradiol and other estrogens (Smith and Dowsett 2003).
Regulation (target) of aromatase enzyme
19) Confidence 0.19 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682397 Disease Relevance 0.35 Pain Relevance 0.13
Taken together, these data indicate that CYP19/aromatase is the major enzyme responsible for the metabolism of methadone to EDDP in term human placentas obtained from healthy pregnancies.
Regulation (responsible) of aromatase in placentas associated with methadone
20) Confidence 0.19 Published 2004 Journal Biochem. Pharmacol. Section Abstract Doc Link 15242824 Disease Relevance 0 Pain Relevance 0.55

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox